ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 2| February2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

ATENOLOL AS A CARDIOSELECTIVE β1-ADRENERGIC BLOCKER: MECHANISM, USES, AND SAFETY PROFILE

K. Panchatcharam[1], P K. Gokul[1], C. Velumurugan[1], N. Kumaran[1], Dr. H. Muhammad Rafeek[2], Dr. N. Gnanasekar[3], Dr. D. Rajalingam[4]

[1]*B Pharm Student, Department of Pharmacology, Kamalakshi Pandurangan College of Pharmacy, Ayyapalayam, Tiruvannamalai-606603, Tamil Nadu, India.*

[2]*Faculty, Department of Pharmacology, Kamalakshi Pandurangan College of Pharmacy, Ayyapalayam, Tiruvannamalai-606603, Tamil Nadu, India.*

[3]*Vice Principal, Department of Pharmacology, Kamalakshi Pandurangan College of Pharmacy, Ayyapalayam, Tiruvannamalai-606603, Tamil Nadu, India.*

[4]*Principal, Department of Pharmaceutical Chemistry, Kamalakshi Pandurangan College of Pharmacy, Ayyapalayam, Tiruvannamalai-606603, Tamil Nadu, India.*

ABSTRACT

Atenolol is a cardio selective β1-adrenergic receptor blocker extensively used in the prevention and treatment of cardiovascular disorders. It produces its therapeutic effects primarily by reducing heart rate, myocardial contractility, and systemic blood pressure, thereby decreasing cardiac workload and oxygen demand. Atenolol has gained wide clinical acceptance due to its relative selectivity for cardiac β1 receptors, which minimizes adverse respiratory and metabolic effects commonly associated with non-selective beta blockers. Its hydrophilic nature limits central nervous system penetration, contributing to improved tolerability during long-term therapy. Atenolol is routinely prescribed for hypertension, chronic stable angina, cardiac arrhythmias, and secondary prevention following myocardial infarction. This review comprehensively discusses the pharmacological profile of atenolol, including its mechanism of action, pharmacological effects, pharmacokinetics, therapeutic applications, adverse reactions, contraindications, drug interactions, and overall clinical relevance.

KEYWORDS: *Atenolol; β1-adrenergic receptor blocker; Cardio selective beta blocker; Hypertension; Angina pectoris; Arrhythmias; Pharmacokinetics; Pharmacodynamics; Adverse drug reactions; Drug–drug interactions; Cardiovascular pharmacotherapy; Renin–angiotensin system.*

1. INTRODUCTION

The second-generation beta-adrenergic receptor antagonist atenolol exhibits significant selectivity for β1 receptors, which are mostly found in cardiac tissue. It was created to lessen the negative impact that first-generation non-selective beta blockers have on the respiratory system and metabolism. Due to its shown effectiveness, safety, and affordability, atenolol has been widely prescribed for a variety of cardiovascular conditions since its release. It is still widely used, especially in low- and middle-income nations, and is recognized as a necessary medication in many healthcare systems. When compared to lipophilic beta blockers, atenolol's hydrophilic nature restricts its ability to cross the blood-brain barrier, resulting in less adverse effects on the central nervous system, including drowsiness, depression, and nightmares. These properties make atenolol suitable for long-term therapy in patients requiring sustained cardiovascular control [1][2].



Fig.1. Chemical structure and molecular formula of Atenolol

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 2| February2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

2. MECHANISM OF ACTION

Atenolol selectively competitively antagonists the heart's β1-adrenergic receptors to provide its therapeutic benefits. Atenolol reduces heart rate, myocardial contractility, and atrioventricular conduction velocity by inhibiting sympathetic activation mediated by catecholamines by the blockage of these receptors. Both cardiac output and myocardial oxygen consumption are lowered as a result.



Fig.2. Cellular mechanism of β1-receptor blockade by Atenolol

Additionally, atenolol reduces renin secretion from the kidneys' juxtaglomerular apparatus, which lowers the production of angiotensin II and the release of aldosterone. Vasodilation and a long-lasting antihypertensive impact are facilitated by this secondary effect. Atenolol is relatively safe in patients with moderate respiratory illness since it shows low β2-receptor blockage at standard therapeutic doses [3][4].

3. PHARMACOLOGICAL ACTIONS

Atenolol's pharmacological effects are mostly limited to the cardiovascular system. It has a negative inotropic effect via lowering myocardial contractile force and a negative chronotropic effect by lowering sinoatrial node firing. Both cardiac output and systemic blood pressure are reduced by these effects. One of atenolol's antiarrhythmic effects is the slowing of atrioventricular conduction.



Fig.3. Physiological effects of Atenolol on the heart

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 2| February2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

The medication increases coronary perfusion and lessens the frequency and intensity of anginal crises by extending diastole. Furthermore, atenolol improves functional ability in ischemic heart disease patients by lowering sympathetic hyperactivity and exercise-induced tachycardia. Consistent beta-blocking actions across various physiological conditions are ensured by the lack of intrinsic sympathomimetic activity [2][5].

4. THERAPEUTIC USES

Atenolol is frequently used to treat essential hypertension and works well when administered alone or in conjunction with calcium channel blockers, angiotensin-converting enzyme inhibitors, or diuretics [8]. Atenolol increases exercise tolerance and lowers myocardial oxygen demand in patients with chronic stable angina by reducing the heart rate response to emotional and physical stress. It is frequently used to treat supraventricular tachyarrhythmias and to regulate ventricular rate in atrial fibrillation [7]. By lowering the risk of reinfarction, arrhythmias, and sudden cardiac death following myocardial infarction, atenolol is crucial for secondary prevention [6]. Its wide therapeutic value is further demonstrated by the treatment of thyrotoxicosis, migraine prophylaxis, and anxiety-related tachycardia [9].



Fig.4. Pharmacokinetic pathway of Atenolol

5. PHARMACOKINETICS

Atenolol is moderately absorbed from the gastrointestinal system after oral dosing, with an oral bioavailability of roughly 50–60% because to incomplete absorption rather than first-pass metabolism. Peak plasma concentrations are reached in two to four hours. Atenolol has a restricted tissue distribution and little penetration of the central nervous system due to its low lipid solubility and low plasma protein binding [4]. The medication is mostly eliminated unaltered by the kidneys by glomerular filtration and active tubular secretion, with minimal hepatic metabolism. For most patients, a once-daily dosage is possible because to the elimination half-life, which is between six and nine hours. The half-life may be prolonged in people with renal impairment, requiring careful monitoring and dose decrease [10].

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 2| February2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

6. ADVERSE EFFECTS

In general, atenolol is well tolerated, especially when used at the authorized dosages. Bradycardia, hypotension, exhaustion, light-headedness, and cold extremities from decreased peripheral circulation are typical side effects. Additionally, gastrointestinal problems such diarrhoea, nausea, and vomiting could happen [11]. Even though atenolol is cardio selective, prolonged or higher dosages may cause bronchospasm, particularly in those who are vulnerable. In certain patients, long-term treatment has been linked to adverse alterations in lipid metabolism and sexual dysfunction. Gradual dose tapering is generally advised since abruptly stopping atenolol might cause rebound tachycardia, hypertension, or angina because of increased sympathetic activity [5].

7. CONTRAINDICATIONS AND PRECAUTIONS

Patients with severe sinus bradycardia, advanced atrioventricular block, cardiogenic shock, and uncompensated heart failure should not use atenolol. Patients with diabetes mellitus should use it cautiously because it may cover up adrenergic hypoglycaemia signs like tremors and tachycardia. Additionally, individuals with peripheral vascular disease, chronic obstructive lung disease, bronchial asthma, and renal impairment must exercise caution. To avoid medication buildup and negative consequences, dose modifications and routine monitoring are crucial for aged patients and those with impaired renal function [1][12].

8. DRUG–DRUG INTERACTIONS

A number of widely used drugs are known to interact with atenolol. When calcium channel blockers like diltiazem and verapamil are administered concurrently, they may cause an excessive reduction in cardiac contractility and conduction, which can result in severe bradycardia or heart block[13]. By preventing prostaglandin synthesis, non-steroidal anti-inflammatory medications can lessen atenolol's antihypertensive effectiveness. Additionally, atenolol may intensify the effects of other antihypertensive medications, raising the possibility of hypotension. Atenolol may conceal hypoglycaemia symptoms when taken with insulin or oral hypoglycaemic medications, requiring close blood glucose monitoring [15].

Fig.5. Clinically significant drug interactions of Atenolol

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 2| February2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

9. CLINICAL SIGNIFICANCE AND RECENT PERSPECTIVES

Because of its proven effectiveness and safety profile, atenolol maintains therapeutic relevance even in the face of the advent of novel beta blockers and antihypertensive medication classes. For individuals who need a cardioselective medication with minimal effects on the central nervous system, it is still the preferable choice[17]. Its role in some populations, such as elderly patients, people with chronic kidney disease, and places with low resources where cost-effective medication is crucial, has been the subject of recent clinical assessments[19]. Atenolol's continued significance in clinical pharmacology is further supported by ongoing studies that compare its efficacy to more recent drugs in terms of long-term cardiovascular outcomes [16][18].

10. CONCLUSION

In contemporary clinical practice, atenolol is still a significant and reputable cardioselective beta blocker. Its selective inhibition of β1-adrenergic receptors lowers the possibility of negative respiratory effects while effectively controlling blood pressure and heart rate. The medication is convenient for long-term usage due to its consistent pharmacokinetic profile, renal elimination, and once-daily dosage. Atenolol has proven to be beneficial in the treatment of arrhythmias, angina pectoris, hypertension, and post-myocardial infarction. Atenolol has considerable therapeutic benefit when taken with cautious dose control, patient selection, and knowledge of interactions and contraindications. Because of its shown effectiveness, safety, and affordability, atenolol maintains its therapeutic significance even in the face of more modern cardiovascular medications.

11. REFERENCES

1. *Katzung BG. Basic & Clinical Pharmacology. McGraw-Hill Education. https://accesspharmacy.mhmedical.com*
2. *Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. McGraw-Hill. https://accesspharmacy.mhmedical.com*
3. *Rang HP, Dale MM, Ritter JM, Flower RJ. Rang & Dale's Pharmacology. Elsevier. https://www.elsevier.com/books/rang-and-dales-pharmacology/9780702074486*
4. *Tripathi KD. Essentials of Medical Pharmacology. Jaypee Brothers Medical Publishers. https://www.jaypeebrothers.com/pgDetails.aspx?book_id=9789354651987*
5. *Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's Manual of Pharmacology and Therapeutics. McGraw-Hill. https://accesspharmacy.mhmedical.com*
6. *Atenolol – Drug Monograph. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK539844/*
7. *Atenolol – Drug Information. DrugBank Online. https://go.drugbank.com/drugs/DB00335*
8. *Meredith PA, Elliott HL. Clinical pharmacokinetics of atenolol. Clinical Pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/6146933/*
9. *Frishman WH. Beta-adrenergic blockers in cardiovascular disease. Journal of Cardiovascular Pharmacology. https://pubmed.ncbi.nlm.nih.gov/2861236/*
10. *Bangalore S, et al. Clinical outcomes with beta-blockers for hypertension. American Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/19896022/*
11. *Yusuf S, et al. Beta-blocker therapy after myocardial infarction. The Lancet. https://pubmed.ncbi.nlm.nih.gov/2899847/*
12. *Chobanian AV, et al. JNC 7 report on hypertension. Hypertension. https://pubmed.ncbi.nlm.nih.gov/14656957/*
13. *Opie LH, Gersh BJ. Drugs for the Heart. Elsevier. https://www.elsevier.com/books/drugs-for-the-heart/9780323444081*
14. *Stockley IH. Stockley's Drug Interactions. Pharmaceutical Press. https://about.medicinescomplete.com/publication/stockleys-drug-interactions/*
15. *Johnson AG. NSAIDs and antihypertensive drug interactions. Drugs. https://pubmed.ncbi.nlm.nih.gov/10776827/*
16. *Messerli FH, et al. Beta-blockers in hypertension revisited. European Heart Journal. https://pubmed.ncbi.nlm.nih.gov/17669458/*
17. *Kaplan NM. Management of hypertension in elderly patients. JAMA. https://pubmed.ncbi.nlm.nih.gov/10634393/*
18. *Whelton PK, et al. 2017 ACC/AHA hypertension guideline. Circulation. https://pubmed.ncbi.nlm.nih.gov/29133356/*
19. *Aronow WS. Beta blockers in cardiovascular disease. Clinical Cardiology. https://pubmed.ncbi.nlm.nih.gov/20882663/*